

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1 – Name and Address of Company:**

Biosenta Inc. (“**Biosenta**”)  
18 Wynford Drive, Suite 704  
Toronto, Ontario  
M3C 3S2

**Item 2 - Date of Material Change:**

April 26, 2024

**Item 3 – News Release:**

The news release attached hereto as Schedule “A” was disseminated over Newsfile Corp. on April 26, 2024.

**Item 4 – Summary of Material Change:**

On April 26, 2024, Biosenta announced the closing of a private placement for gross proceeds of \$600,000 (the "**Offering**"). Biosenta issued 1,500,000 units (each, a "**Unit**") under the Offering at a price of \$0.40 per Unit, with each Unit consisting of one common share in the capital of the Company (each, a "**Common Share**") and one half of one Common Share purchase warrant (each whole warrant, a "**Warrant**"). Each Warrant entitles its holder to acquire one Common Share at a price of \$0.80 for a period of 18 months from the closing date of the Offering.

**Item 5 – Full Description of Material Change:**

**5.1 Full Description of Material Change**

On April 26, 2024, Biosenta announced the closing of a private placement for gross proceeds of \$600,000 (the "**Offering**"). Biosenta issued 1,500,000 units (each, a "**Unit**") under the Offering at a price of \$0.40 per Unit, with each Unit consisting of one common share in the capital of the Company (each, a "**Common Share**") and one half of one Common Share purchase warrant (each whole warrant, a "**Warrant**"). Each Warrant entitles its holder to acquire one Common Share at a price of \$0.80 for a period of 18 months from the closing date of the Offering.

The securities issued pursuant to the Offering shall be subject to a four-month plus one day “hold period” expiring August 27, 2024, as prescribed by applicable Canadian securities laws.

As a result of closing the Offering, there are 31,738,888 Common Shares of Biosenta issued and outstanding on a non-diluted basis.

The Company intends to use the net proceeds from the Offering for general corporate purposes.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**Item 6 – Reliance on subsection 7.1(2) of National Instrument 51-102:**

Not applicable.

**Item 7 - Omitted Information:**

Not applicable.

**Item 8 – Executive Officer:**

Am Gill  
President and Chief Executive Officer  
416-410-2019

**Item 9 – Date of Report:**

May 8, 2024